ライフサイエンスコーパス: azimilide

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 th QT prolongation induced by dl-sotalol and azimilide.

2 was significantly prolonged in the combined azimilide 100 mg and 125 mg daily dose group compared wi

3 first symptomatic recurrence in the combined azimilide 100 mg and 125 mg dose groups with that in the

4 d, placebo-controlled, double-blind study of azimilide 100 mg on all-cause mortality.

5 Of note, although azimilide (3 to 10 micromol/L) increased APD more than d

6 lation or atrial flutter received placebo or azimilide (35 to 125 mg) once daily for 6 or 9 months in

7 Azimilide 50 mg, 100 mg or 125 mg was tested; the primar

8 Oral azimilide (75 to 125 mg/day) was taken by 5,375 patients

9 his study was to assess the effectiveness of azimilide, a class III antiarrhythmic drug, in reducing

10 Azimilide, a novel class III antiarrhythmic drug, was in

11 lation occurred in 49 of 382 (13%) receiving azimilide and 43 of 233 (18%) receiving placebo.

12 oaches under active investigation, including azimilide and dronedarone, are compounds with multiple e

13 are emerging regarding clinical efficacy of azimilide and dronedarone.

14 differences were observed between the 100-mg azimilide and placebo groups for all-cause mortality in

15 supportive (as has occurred with sotalol and azimilide), and patients who are to receive amiodarone.

16 Azimilide-associated TdP has characteristics and risk fa

17 The azimilide-associated TdP rate is 1% (95% confidence inte

18 cteristics, and risk factors associated with azimilide-associated torsades de pointes (TdP) ventricul

19 ction in asymptomatic atrial fibrillation on azimilide compared with placebo (P=0.03) when repeated o

20 Significantly fewer patients receiving azimilide developed atrial fibrillation than did patient

21 Azimilide did not improve or worsen the mortality of pat

22 this study was to assess the effect of oral azimilide dihydrochloride (AZ) 100 mg versus placebo on

23 This study evaluated the effects of azimilide dihydrochloride (AZ) on anti-tachycardia pacin

24 Azimilide dihydrochloride is a class III antiarrhythmic

25 Azimilide dihydrochloride may be a safe and effective dr

26 Azimilide dihydrochloride was generally well tolerated a

27 Azimilide dihydrochloride was investigated as adjunctive

28 7.96, p = 0.005); the hazard ratio (placebo: azimilide) for this comparison was 1.58 (95% confidence

29 00 cells/microL) were slightly higher in the azimilide group than in the placebo group (0.3% versus 0

30 l epithelium was: Ba2+ > clofilium >>> TEA = azimilide >>> trans-6-cyano-4-(N-ethylsulphonyl-N-methyl

31 Unlike dl-sotalol, azimilide (>3 micromol/L) increased epicardial APD marke

32 Azimilide, however, significantly prolonged APD and QT i

33 In the 3 trials evaluating azimilide in therapeutic doses (100 and 125 mg), asympto

34 multiple ionic channels (e.g., ibutilide and azimilide) in order to prolong atrial and ventricular ac

35 related, and tended to occur earlier with an azimilide-loading regimen.

36 Azimilide may reduce the occurrence of this silent arrhy

37 n (AF) in a subpopulation of patients in the Azimilide Postinfarct Survival Evaluation (ALIVE) trial.

38 Although both dl-sotalol and azimilide rarely induced EADs in canine left ventricles,

39 ed to receive once daily doses of placebo or azimilide; recurrent symptomatic arrhythmias were docume

40 Azimilide significantly lengthened the symptomatic arrhy

41 ic epithelium the order was: Ba2+ = 293B >>> azimilide = TEA >>> clofilium = charybdotoxin.

42 Azimilide was investigated for its effects on mortality

43 Azimilide was safe and effective AF therapy in patients

44 The TdP occurred in 56 patients assigned to azimilide, was dose-related, and tended to occur earlier

45 ical use soon, and it is currently reviewing azimilide (which seems to be devoid of frequency-depende

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。